A side effect resource to capture phenotypic effects of drugs
Open accessAbstract
The molecular understanding of phenotypes caused by drugs in humans is essential for elucidating mechanisms of action and for developing personalized medicines. Side effects of drugs (also known as adverse drug reactions) are an important source of human phenotypic information, but so far research on this topic has been hampered by insufficient accessibility of data. Consequently, we have developed a public, computer-readable side effect resource (SIDER) that connects 888 drugs to 1450 side effect terms. It contains information on frequency in patients for one-third of the drug-side effect pairs. For 199 drugs, the side effect frequency of placebo administration could also be extracted. We illustrate the potential of SIDER with a number of analyses. The resource is freely available for academic research at http://sideeffects.embl.de.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about drug-target interactions.
“Notably, high-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about the drug-target interactions.29,30”
From Drug repurposing for cancer therapy (2024) · cites this paper as [30]
The Introduction (page unavailable) discusses databases of cellular phenotypes and the potential of large-scale computational methods; it does not describe screening sophisticated models to find compounds that relieve disease symptoms. Searches for high-throughput screening, symptom mitigation, and drug-target-independent screening found no passage addressing that claim. (LLM, conf=0.73)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784 · see citing works
Flagged first, then by citations
Research works printed but not linked: 14
- Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673– 683 15286734
- Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem Med Chem 2: 861– 873 17477341
- Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263– 266 18621671
- Fliri AF, Loging WT, Volkmann RA (2007) Analysis of system structure-function relationships. Chem Med Chem 2: 1774– 1782 17952882
- Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC (2003) Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Devel 6: 470– 480 12951810
- Kuhn M, Campillos M, González P, Jensen LJ, Bork P (2008) Large-scale prediction of drug-target relationships. FEBS Lett 582: 1283– 1290 18291108
- Liebler DC, Guengerich FP (2005) Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 4: 410– 420 15864270
- Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35: D198– D201 17145705 PMC1751547
- Lue TF (2000) Erectile dysfunction. N Engl J Med 342: 1802– 1813 10853004
- Pafilis E, O'Donoghue SI, Jensen LJ, Horn H, Kuhn M, Brown NP, Schneider R (2009) Reflect: augmented browsing for the life scientist. Nat Biotechnol 27: 508– 510 19513049
- Seiler KP, George GA, Happ MP, Bodycombe NE, Carrinski HA, Norton S, Brudz S, Sullivan JP, Muhlich J, Serrano M, Ferraiolo P, Tolliday NJ, Schreiber SL, Clemons PA (2008) ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 36: D351– D359 17947324 PMC2238881
- Shiri R, Koskimaki J, Hakkinen J, Auvinen A, Tammela TL, Hakama M (2007) Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 19: 208– 212 16900205
- Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S, Geer LY, Kapustin Y, Khovayko O, Landsman D, Lipman DJ, Madden TL, Maglott DR, Ostell J, Miller V, Pruitt KD (2007) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 35: D5– 12 17170002 PMC1781113
- Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901– D906 18048412 PMC2238889
Cited by
Sorted by citations
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · see citing works
The SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · see citing works
Self-citationData-driven prediction of drug effects and interactions
Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003377 · Cited by 936 · see citing works
Network-based in silico drug efficacy screening
Guney, E., Menche, J., Vidal, M., & Barábasi, A.-L. (2016) · Nature Communications · doi:10.1038/ncomms10331 · Cited by 625 · see citing works
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443 · see citing works
“29,30 Current computational methodologies, such as merging drug effects with clinical disease signatures and model systems that predict disease-modifying effects, are available for the selection of drug candidates suitable for drug repurposing in cancer.”
BackgroundWan, F., Hong, L., Xiao, A., Jiang, T., & Zeng, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty543 · Cited by 381 · see citing works
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361 · see citing works
Target identification among known drugs by deep learning from heterogeneous networks
Zeng, X., Zhu, S., Lu, W., Liu, Z., Huang, J., Zhou, Y., Fang, J., Huang, Y., Guo, H., Li, L., et al. (2020) · Chemical Science · doi:10.1039/c9sc04336e · Cited by 357 · see citing works
A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.023 · Cited by 310 · see citing works
Information retrieval and text mining technologies for chemistry
Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281 · see citing works
Machine Learning for Drug-Target Interaction Prediction
Chen, R., Liu, X., Jin, S., Lin, J., & Liu, J. (2018) · Molecules · doi:10.3390/molecules23092208 · Cited by 292 · see citing works
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228 · see citing works
Thafar, M. A., Olayan, R. S., Ashoor, H., Albaradei, S., Bajic, V. B., Gao, X., Gojobori, T., & Essack, M. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00447-2 · Cited by 143 · see citing works
Comprehensive prediction of drug-protein interactions and side effects for the human proteome
Zhou, H., Gao, M., & Skolnick, J. (2015) · Scientific Reports · doi:10.1038/srep11090 · Cited by 138 · see citing works
Peng, J., Li, J., & Shang, X. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03677-1 · Cited by 133 · see citing works
Learning for Personalized Medicine: A Comprehensive Review From a Deep Learning Perspective
Zhang, S., Bamakan, S. M. H., Qu, Q., & Li, S. (2019) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2018.2864254 · Cited by 125 · see citing works
Adverse drug events: database construction and in silico prediction
Cheng, F., Li, W., Wang, X., Zhou, Y., Wu, Z., Shen, J., & Tang, Y. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4000079 · Cited by 124 · see citing works
Development and evaluation of an ensemble resource linking medications to their indications
Wei, W.-Q., Cronin, R. M., Xu, H., Lasko, T. A., Bastarache, L., & Denny, J. C. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001431 · Cited by 106 · see citing works
Drug–target interaction predication via multi-channel graph neural networks
Li, Y., Qiao, G., Wang, K., & Wang, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab346 · Cited by 112 · see citing works
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Wu, L., Ingle, T., Liu, Z., Zhao-Wong, A., Harris, S., Thakkar, S., Zhou, G., Yang, J., Xu, J., Mehta, D., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2628-5 · Cited by 80 · see citing works
Yang, X., Bian, J., Fang, R., Bjarnadottir, R. I., Hogan, W. R., & Wu, Y. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz144 · Cited by 74 · see citing works
Fang, H., Harris, S. C., Liu, Z., Zhou, G., Zhang, G., Xu, J., Rosario, L., Howard, P. C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.006 · Cited by 56 · see citing works
In silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49 · see citing works
Zhou, H., Cao, H., Matyunina, L., Shelby, M., Cassels, L., McDonald, J. F., & Skolnick, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01248 · Cited by 39 · see citing works
Wang, Z., Guo, K., Gao, P., Pu, Q., Wu, M., Li, C., & Hur, J. (2020) · arXiv · doi:10.48550/arxiv.2005.07856 · Cited by 9 · see citing works
- Authors
- Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (DE)
- University of Copenhagen (DK)
- Venue
- Molecular Systems Biology
- Published
- 2010-01-19
- Volume
- 6
- Issue
- 1
- Pages
- 343-343
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC2824526
- OpenAlex
- W2142572836
- Cited by
- 899
- References
- 1
- Citations by year
- 2026: 10 · 2025: 40 · 2024: 35 · 2023: 57 · 2022: 50 · 2021: 46 · 2020: 44 · 2019: 64 · 2018: 72 · 2017: 55 · 2016: 80 · 2015: 102 · 2014: 73 · 2013: 70 · 2012: 47
- FWCI
- 72.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Systems Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute on Drug Abuse
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biomedical Text Mining and Ontologies
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Keywords
- adverse drug reactions, SIDER, drug mechanisms of action, personalized medicine
- MeSH terms
- Pharmaceutical Preparations, Humans, Phenotype, Structure-Activity Relationship, Adverse Drug Reaction Reporting Systems, Risk Assessment, Databases as Topic, Internet, Data Mining, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
